Drug resistance interpretation: PR HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None

PLAccessory Mutations: None

PR Other Mutations: L100 pm - L19V pm - N37H pm - 147IM pm - L63Q pm - 172V pm - V77I pm - L72V

Protease Inhibitors

Susceptible atazanavir/r (ATV/r) darunavir/r (DRV/r) Susceptible Susceptible fosamprenavir/r (FPV/r) indinavir/r (IDV/r) Susceptible lopinavir/r (LPV/r) Susceptible nelfinavir (NFV) Susceptible saquinavir/r (SQV/r) Susceptible tipranavir/r (TPV/r) Susceptible

PR comments

Mutation scoring: PR

Other

- L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.
- . IATV is a non-polymorphic PI-selected mutation associated with reduced susceptibility to LPV and DRV. IATM is a highly unusual mutation at this position.

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT HIVDB 9.5.1 (2023-11-05)

RT Other Mutations: K20R - V35I - T39A - V60I - K122E - D123G - H35T - H42V - K173A - D177E - D177E - T200A - C207E - R211K - F214L - F214L - C207E -

Nucleoside Reverse Transcriptase Inhibitors

Susceptible

Low-Level Resistance
Susceptible
Susceptible
Potential Low-Level Resistance
High-Level Resistance
High-Level Resistance

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

efavirenz (EFV)

High-Level Resistance

etravirine (ETR)

nevirapine (NVP)

rilpivirine (RPV)

High-Level Resistance

High-Level Resistance

RT comments

abacavir (ABC)

zidovudine (AZT)

stavudine (D4T)

didanosine (DDI)

emtricitabine (FTC)

lamivudine (3TC)

tenofovir (TDF)

NRTI

• M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

NNRTI

Y188L is a non-polymorphic mutation that confers high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.

ouici .

V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

Drug resi	stance mu	Download CSV					
Rule	ABC ÷	AZT ≑	D4T ÷	DDI ÷	FTC ÷	зтс ≑	TDF
M184V	15	-10	-10	10	60	60	-10

Drug resistance mutation scores of NNRTI:

Rule	DOR ‡	EFV ‡	ETR ≑	NVP ≑	RPV ≑
Y188L	60	60	10	60	60